AAN 2026 | Frexalimab among exciting new developments in multiple sclerosis treatment
Regina Berkovich, MD, PhD, University of Southern California, Los Angeles, CA, comments on the variety of disease-modifying therapies available for multiple sclerosis (MS) and expresses gratitude to patients who participate in clinical trials. Dr Berkovich is particularly excited about frexalimab, a new medication being explored for the treatment of MS. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that we have a great variety of different disease-modifying therapies, but we also have some new classes coming, which is very exciting. And I would like to express my deepest gratitude to those patients who agree to participate in the clinical trials and help us to bring to the market, to make it available to other MS patients, to all of MS patients, new classes of disease-modifying therapies...
I think that we have a great variety of different disease-modifying therapies, but we also have some new classes coming, which is very exciting. And I would like to express my deepest gratitude to those patients who agree to participate in the clinical trials and help us to bring to the market, to make it available to other MS patients, to all of MS patients, new classes of disease-modifying therapies. This is a great bravery of those patients who would like to participate and also selflessness. And I’m very, very grateful to all of our patients who would like to offer their time and efforts in delivering to the larger MS community new MS medications and very much looking forward to the new era of the drugs. I’m especially quite excited about the frexalimab, which is a great concept of the medication working on different parts of the immune system, one on both innate and adaptive immune system, which both participate largely in the immunology of MS. And this medication, as far as we can see, is of immunomodulatory effects, not of immunosuppressive in terms of cell depletion. We don’t see the lymphopenia. We don’t see immunoglobulin deviations, at least not at the moment with this medication. And that’s why I think that would be a great option for those patients who may need to consider a different or new disease-modifying therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
